• OTS
  • March 31, 2020
SHARE
Post Views: 603

Frank DE, Schnell FJ, Akana C, El-Husayni SH, Desjardins CA, Morgan J, Charleston JS, Sardone V, Domingos J, Dickson G, Straub V, Guglieri M, Mercuri E, Servais L, Muntoni F; SKIP-NMD Study Group.
Neurology. 2020 Mar 5.

PubMed

Related articles

Tilsotolimod with ipilimumab drives tumor responses in anti-PD-1 refractory melanoma

Tilsotolimod with ipilimumab drives tumor responses in anti-PD-1 refractory melanoma

April 23rd, 2021
A targeted antisense therapeutic approach for Hutchinson-Gilford progeria syndrome

A targeted antisense therapeutic approach for Hutchinson-Gilford progeria syndrome

April 23rd, 2021
Super-resolution RNA imaging using a rhodamine-binding aptamer with fast exchange kinetics

Super-resolution RNA imaging using a rhodamine-binding aptamer with fast exchange kinetics

March 15th, 2021
Perspectives on the Designation of Oligonucleotide Starting Materials

Perspectives on the Designation of Oligonucleotide Starting Materials

March 15th, 2021
Treatment of influenza and SARS-CoV-2 infections via mRNA-encoded Cas13a in rodents

Treatment of influenza and SARS-CoV-2 infections via mRNA-encoded Cas13a in rodents

March 15th, 2021
Splicing-associated chromatin signatures: a combinatorial and position-dependent role for histone marks in splicing definition

Splicing-associated chromatin signatures: a combinatorial and position-dependent role for histone marks in splicing definition

February 16th, 2021